The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
|Articles|March 6, 2006
- Applied Clinical Trials-03-06-2006
- Volume 0
- Issue 0
PRA International Names Dr. Cynthia Kirk Vice President of Global Regulatory Affairs
Dr. Cynthia Kirk has joined PRA International as Vice President, Global Regulatory Affairs.
Advertisement
RESTON, Va., February 14, 2006 – PRA International (Nasdaq: PRAI), one of the world's leading global clinical research organizations (CROs), today announced Dr. Cynthia Kirk has joined the company as Vice President, Global Regulatory Affairs.
Most recently, Dr. Kirk was Vice President of Regulatory Affairs at Sepracor Inc., a research-based pharmaceutical company with a focus on respiratory and central nervous system disorders. Dr. Kirk is currently President-Elect of the Drug Information Association (DIA). She is a graduate of the University of Missouri-Kansas City, qualifying as a Ph.D. in Pharmaceutical Sciences with a concentration in Pharmacology/Toxicology.
"Our clients are increasingly looking to us to help them navigate complex regulatory structures on a global basis," said Dr. Monika Pietrek, Executive Vice President, Global Scientific and Medical Affairs. "Dr. Kirk's pharmacology experience, industry knowledge and regulatory acumen further our ability to support their drug development efforts."
Prior to joining Sepracor, Dr. Kirk held several senior level positions in regulatory affairs at pharmaceutical companies and in the CRO industry, where she represented numerous companies before the U.S. Food and Drug Administration as a strategic liaison for products reviewed and approved across various FDA divisions.
"PRA International presents me with an exceptional opportunity to work with leading pharmaceutical and biotech companies that are defining the future of medicine," said Dr. Kirk. "I look forward to helping our clients formulate their regulatory and safety strategies."
Articles in this issue
over 20 years ago
Fighting for Europe's Futureover 20 years ago
Oracle Introduces Oracle® Clinical Data Repositoryover 20 years ago
Interview with Klaus Roseover 20 years ago
Pictures from Parisover 20 years ago
EU Innovation and CompetitivenessAdvertisement
Related to this article
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.
In today’s ACT Brief, we examine why anti-kickback guidance and EHR-integrated trial matching must work together in community settings, why real-time trials depend on mature risk-based quality management, and how pharma is applying digital clones to predict outcomes.
The FDA’s RTCT initiative transmits predefined, clinically meaningful signals to regulators during active trials, so its value depends entirely on the maturity of sponsors’ upstream RBQM signal intelligence, KRIs, QTLs, and root-cause context, rather than on data speed.
In this video interview, Kent Thoelke, CEO of Paradigm Health, outlines why anti-kickback guidance and modern EHR-integrated trial matching technology must work in tandem to reach representative patient populations at the community level.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
2
What Needs to Happen Beyond the Clinical Trial Modernization Act
3
Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas
4
Real-Time Continuous Trials Through the Lens of Risk-Based Quality Management: Why RBQM Is the Infrastructure RTCT Cannot Exist Without
5